Pharmaceuticals News

ASHBURN, Va., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical-stage specialty pharmaceutical company focused on rare and...

Quoin Pharmaceuticals (NASDAQ: QNRX) interim Phase 2/3 data in Netherton Syndrome met the primary endpoint, with four of six patients responding.

BioXcel Therapeutics intends to complete a court-supervised sale transaction, in an effort to maximize value for all stakeholders Teva Pharmaceuticals to serve as “stalking horse” bidder in a...

CDT Validates Enhanced Solid-Form Properties Within Its IP Portfolio

-- Chiesi’s abstract presentations highlight clinical insights and patient-reported outcomes in Fabry disease and alpha-mannosidosis -- -- Rooted in patient voice and scientific rigor, this research...

The SALWEEN study showed significant improvements in vision and retinal health1 More than 60% of Asian patients with polypoidal choroidal vasculopathy (PCV), an aggressive subtype of nAMD, treated...

-- Chiesi’s abstract presentations highlight clinical insights and patient-reported outcomes in Fabry disease and alpha-mannosidosis -- -- Rooted in patient voice and scientific rigor, this research...

OSE Immunotherapeutics to host a KOL webcast dedicated to lusvertikimab on September 2, 2026

NANTES, France, le 28 août 2026, 7h30 CET – OSE Immunotherapeutics SA (ISIN : FR0012127173 ; Mnemo : OSE) (la « Société »), annonce aujourd’hui que la Société organisera un webcast avec des experts...

Kardium meddelade den 27 augusti att Kanadas regering beviljar bolaget investeringsstöd om upp till 31,25 miljoner kanadensiska dollar genom Strategic Response Fund. Stödet avser Kardiums investering...